<DOC>
	<DOCNO>NCT00071188</DOCNO>
	<brief_summary>The purpose run-in phase study determine appropriate tolerable dose ZD6474 ( 200mg 300mg ) administer combination paclitaxel carboplatin subject previously untreated locally advanced metastatic NSCLC . This phase trial close enrollment . The purpose randomized phase study determine efficacy ZD6474 alone versus ZD6474 combination paclitaxel carboplatin versus paclitaxel carboplatin alone subject previously untreated locally advanced metastatic NSCLC . This phase trial close enrollment .</brief_summary>
	<brief_title>ZD6474 Alone Combination With Paclitaxel Carboplatin Subjects With Previously Untreated Locally Advanced Metastatic Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Signed informed consent 18 year old Histologically cytologically confirm locally advanced metastatic NSCLC No prior chemotherapy/biological therapy/radiation therapy One measurable lesion Life expectancy 12 week Brain metastasis spinal cord compression Currently active skin disease History significant hemoptysis Abnormal blood chemistry Cardiac abnormalities Recent significant cardiac event Coexisting malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Non-Small-Cell Lung Carcinoma</keyword>
</DOC>